BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 18195669)

  • 1. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
    Guthrie R
    Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MATCH results: implications for the internist.
    Lutsep HL
    Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
    Hankey GJ
    Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
    Gorelick P; Sechenova O; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic drugs for the secondary prevention of ischemic stroke.
    Nenci GG; Goracci S
    Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 16. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
    Fisher M
    Arch Neurol; 2006 Jan; 63(1):20-4. PubMed ID: 16401733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Hankey GJ; Eikelboom JW
    Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The approach to optimizing stroke care.
    Panagos PD
    Am J Emerg Med; 2008 Sep; 26(7):808-16. PubMed ID: 18774049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet therapy in the prevention of ischaemic stroke.
    Verry M; Panak E; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.